Category: Expense Monitoring & Auditing

Explore our library of blogs, insights, research papers, and more information on compliance in the life sciences industry.

I’ve been reading an excellent paper on introducing, implementing, and measuring the effectiveness of transparency metrics for software systems. And while reflecting on it, I realized that the principles and methodology discussed are applicable for the pharmaceutical compliance space too. While the paper concedes the obscure nature of transparency, it establishes that metrics for transparency […]

Slightly over two months ago, applicable manufacturers in North America added to the 40.74 million records already present in the CMS Open Payments database. This exercise will also add to the $24.92 billion worth of Transfers of Value (TOVs) already covered in the database since 2013. So why do companies make the laborious effort of […]

“What Role Is Technology Playing In Helping You Become GDPR Compliant?” We asked this question (or rather, a version of it) during a survey at our recent GDPR Life Sciences Bootcamp. The respondents were uniformly compliance/transparency professionals from the life sciences industry. Any guesses on what their response was? Less than 10% were able to […]

A few weeks ago, as we briefly covered news on Insys Therapeutics, we realized that the ripples of its scandal would be felt across the pond. And indeed, qordata finds many compliance professionals in the EU pharma industry voicing concerns about the possibility of something like this happening in their own markets. The fact that […]

There’s a reason business lingo has so much of what I would call ‘war words’: Starting with the all-famous “strategy”, to “target”, “guerilla tactics,” “mission,” “red ocean” and so on. The way I see it, the reason is that in war as in business, rivals compete ruthlessly for the same reward in a challenging and […]

In the American medical drug and device industry, poor compliance practices never go away. They keep coming back to haunt you in newer and more alarming ways. Take Insys Therapeutics, Inc. In less than three years, it has gained infamy for using unethical means (read: violation of good pharmaceutical compliance practices) to sell its opioid, […]